fexinidazole has been researched along with atovaquone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azas, N; Cantelli, C; Casanova, M; Castera-Ducros, C; Cohen, A; Crozet, MD; Hutter, S; Laget, M; Paloque, L; Rathelot, P; Remusat, V; Tanguy, F; Vanelle, P; Verhaeghe, P | 1 |
| Azas, N; Basmaciyan, L; Belle Mbou, V; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, É; Casanova, M; Castera-Ducros, C; Cohen, A; Courtioux, B; Fairlamb, AH; Fersing, C; Hutter, S; Laget, M; Milne, R; Pedron, J; Piednoel, M; Primas, N; Rathelot, P; Since, M; Sournia-Saquet, A; Valentin, A; Vanelle, P; Verhaeghe, P; Wyllie, S | 1 |
2 other study(ies) available for fexinidazole and atovaquone
| Article | Year |
|---|---|
Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.
Topics: Animals; Antiprotozoal Agents; Cell Line; Cell Survival; Drug Evaluation, Preclinical; Hep G2 Cells; Humans; Imidazoles; Leishmania donovani; Mice; Pyridines; Structure-Activity Relationship | 2013 |
Nongenotoxic 3-Nitroimidazo[1,2-
Topics: | 2019 |